Valuation: PolyNovo Limited

Capitalization 836M 557M 474M 443M 415M 768M 50.26B 5.16B 2B 23.74B 2.09B 2.05B 86.51B P/E ratio 2026 *
52.5x
P/E ratio 2027 * 33.9x
Enterprise value 804M 536M 456M 426M 400M 739M 48.36B 4.96B 1.93B 22.85B 2.01B 1.97B 83.25B EV / Sales 2026 *
5.06x
EV / Sales 2027 * 4.03x
Free-Float
88.99%
Yield 2026 *
-
Yield 2027 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-2.42%
1 week+0.83%
Current month-1.63%
1 month-1.22%
3 months-17.12%
6 months-7.28%
Current year-40.69%
More quotes
1 week 1.18
Extreme 1.175
1.25
1 month 1.1
Extreme 1.105
1.25
Current year 0.93
Extreme 0.93
2.36
1 year 0.93
Extreme 0.93
2.36
3 years 0.93
Extreme 0.93
2.78
5 years 0.84
Extreme 0.835
4.08
10 years 0.14
Extreme 0.145
4.08
More quotes
Manager TitleAgeSince
Chief Executive Officer - 2025-11-30
Director of Finance/CFO - 2018-12-11
Chief Tech/Sci/R&D Officer - 2021-11-30
Director TitleAgeSince
Chairman - 2025-10-26
Director/Board Member 64 2019-10-27
Director/Board Member - 2020-05-12
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-2.42%+0.83%-42.92%-37.79% 571M
+0.98%-0.52%+9.28%+13.65% 214B
-0.08%-1.63%+20.52%+25.09% 128B
+0.69%+2.18%+49.52%+107.57% 66.83B
-0.35%+3.13%-11.94%-21.26% 57.21B
+1.79%+0.23%+17.62%+71.97% 51.16B
-2.28%+2.54%-14.92%-42.49% 26.89B
-0.36%-4.43%+16.27%+29.18% 24.78B
-1.06%-3.80%+5.39%-35.53% 23.72B
+0.63%-4.56%-23.93%+16.41% 21.83B
Average -0.23%-0.25%+2.49%+12.68% 61.52B
Weighted average by Cap. +0.41%-0.82%+12.56%+24.16%
See all sector performances

Financials

2026 *2027 *
Net sales 159M 106M 90.22M 84.24M 79.03M 146M 9.57B 981M 381M 4.52B 398M 390M 16.46B 195M 130M 110M 103M 96.65M 179M 11.7B 1.2B 466M 5.53B 487M 476M 20.13B
Net income 15.24M 10.16M 8.64M 8.07M 7.57M 14M 916M 94.01M 36.53M 433M 38.12M 37.31M 1.58B 23.92M 15.94M 13.56M 12.66M 11.88M 21.97M 1.44B 148M 57.33M 679M 59.83M 58.56M 2.48B
Net Debt -31.53M -21.02M -17.88M -16.7M -15.66M -28.96M -1.9B -195M -75.58M -896M -78.87M -77.2M -3.26B -52.52M -35.01M -29.79M -27.81M -26.09M -48.24M -3.16B -324M -126M -1.49B -131M -129M -5.44B
More financial data * Estimated data
Logo PolyNovo Limited
PolyNovo Limited is an Australia-based medical device company, which is focused on advanced wound care that designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.
Employees
301
More about the company
Date Price Change Volume
25-12-12 1.210 $ -2.42% 1,651,027
25-12-11 1.240 $ +1.64% 1,570,649
25-12-10 1.220 $ +2.09% 1,213,163
25-12-09 1.195 $ +0.42% 988,950
25-12-08 1.190 $ -1.24% 672,871

Delayed Quote Australian S.E., December 12, 2025 at 12:10 am EST

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.210AUD
Average target price
1.919AUD
Spread / Average Target
+58.62%
Consensus

Quarterly revenue - Rate of surprise